本文選題：復(fù)方牛胎肝提取物片　切入點：乙型病毒性肝炎　出處：《中國臨床藥理學(xué)雜志》2015年12期 　論文類型：期刊論文

【摘要】：目的評價拉米夫定聯(lián)合復(fù)方牛胎肝提取物片治療慢性乙型病毒性肝炎(慢性乙肝)患者肝纖維化的臨床療效及安全性。方法將66例慢性乙肝患者隨機(jī)分為對照組34例和試驗組32例。對照組給予口服拉米夫定100 mg qd,療程為6個月;試驗組在對照組的基礎(chǔ)上,給予口服復(fù)方牛胎肝提取物片80 mg,tid,療程為6個月。比較2組患者治療前后的Ⅲ型前膠原、玻璃酸等肝纖維化指標(biāo)、肝穿刺活檢炎癥評分、肝纖維化評分以及不良反應(yīng)發(fā)生率。結(jié)果治療6個月后,2組患者肝纖維化指標(biāo)較治療前均有明顯好轉(zhuǎn),但試驗組血清玻璃酸、層黏連蛋白和Ⅲ型前膠原指標(biāo)明顯低于對照組(P0.05)。治療后,試驗組肝穿刺活檢肝炎癥評分及肝纖維化評分顯著低于對照組(P0.05)。試驗組不良反應(yīng)發(fā)生率為29.41%,對照為21.88%,2組比較差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論拉米夫定聯(lián)合復(fù)方牛胎肝提取物片可顯著改善慢性乙肝患者肝纖維化程度,預(yù)防肝損傷。
[Abstract]:Objective to evaluate the efficacy and safety of lamivudine combined with compound bovine fetal liver extract tablets in the treatment of liver fibrosis in patients with chronic hepatitis B. methods 66 patients with chronic hepatitis B were randomly divided into control group. 34 cases and 32 cases in the test group. The control group was given 100mg / d lamivudine orally for 6 months. On the basis of the control group, the experimental group was given 80 mg of compound bovine fetal liver extract tablets for 6 months. The hepatic fibrosis indexes such as type 鈪，

本文編號：1645513